Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: Candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease

Neuroscience Letters

Volumn 436, Issue 2, 2008, Pages 153-157

  Jung, Sang Min ^a   Lee, KiBeom ^a   Lee, Joung Wook ^b   Namkoong, Hong ^a   Kim, Hyun Kee ^a   Kim, Sanghee ^a   Na, Hae Ri ^b   Ha, Seon Ah ^a   Kim, Jae Ryong ^c   Ko, Jesang ^d   Kim, Jin Woo ^a  

^a The Catholic University of Korea   (South Korea)

^b Bobath Memorial Hospital   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Korea University   (South Korea)

Author keywords

Alzheimer's disease; Biological markers; Cerebrospinal fluid; Cognitive impairment; Haptoglobin precursor allele 1; Plasma retinol binding protein; Proteomics

Indexed keywords

HAPTOGLOBIN; RETINOL BINDING PROTEIN;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; COGNITION DISORDERS; DISEASE PROGRESSION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HAPTOGLOBINS; HUMANS; MALE; RETINOL-BINDING PROTEINS;

EID: 42049083159     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.03.010     Document Type: Article

References (31)

1. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winbald B., and Blennow K. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58 3 (2001) 373-379
2. Blennow K. Cerebropinal fluid protein biomarkers for Alzhiemer's disease. Neuro. Rx. 1 2 (2004) 213-225
3. Blennow K., Davidsson P., Wallin A., Gottfries C.G., and Svennerholm L. Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia. Int. Psychogeriatr. 6 1 (1994) 13-22
4. Blum H., Beier H., and Gross H.J. Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels. Electrophoresis 8 (1987) 93-99
5. Choe L.H., Dutt M.J., Relkin N., and Lee K.H. Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis 23 (2002) 2247-2251
6. Davidsson P., and Sjögren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis. Markers 21 2 (2005) 81-92
7. Davidsson P., Westman-Brinkmalm A., Nilsson C.L., Lindbjer M., Paulson L., Andreasen N., Sjogren M., and Blenow K. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuro. Rep. 13 5 (2002) 611-615
8. de la Monte S.M., Volicer L., Hauser S.L., and Wands J.R. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 32 6 (1992) 733-742
9. Fenoglio C., Galimberti D., Lovati C., Guidi I., Gatti A., Fogliarino S., Tiriticco M., Mariani C., Forloni G., Pettenati C., Baron P., Conti G., Bresolin N., and Scarpini E. MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiol. Aging 25 9 (2004) 1169-1173
10. Ghanbari K., and Ghanbari H. A sandwich enzyme immunoassay for measuring AD7C-NTP as an Alzheimer's disease marker: AD7C test. J. Clin. Lab. Anal. 12 4 (1998) 223-226
11. Hanley J.M., and Heath E.C. A novel proteolytic activity in serum processes rat prohaptoglobin. Arch. Biochem. Biophys. 239 2 (1985) 404-419
12. Haugen T.H., Hanley J.M., and Heath E.C. Haptoglobin. A novel mode of biosynthesis of a liver secretory glycoprotein. J. Biol. Chem. 256 3 (1981) 1055-1057
13. Hu Y.Y., He S.S., Wang X.C., Duan Q.H., Khatoon S., Iqbal K., Grundke-Iqbal J.Z., and Wang. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci. Lett. 320 3 (2002) 156-160
14. Irizarry M.C. Biomarkers of Alzheimer disease in plasma. Neuro. Rx. 1 2 (2004) 226-234
15. Johnson G., Brane D., Block W., Kammen D.P., Gurklis J., Peters J.L., Wyatt R.J., Kirch D.G., Ghanbari H.A., and Merril C.R. Cerebrospinal fluid protein variations in common to Alzheimer's disease and schizophrenia. Appl. Theor . Electrophor. 3 2 (1992) 47-53
16. Kanai M., Raz A., and Goodman D. Retinol binding protein: the transport protein for vitamin A in human plasma. J. Clin. Invest. 47 9 (1968) 2025-2044
17. Kawas C.H., and Katzman R. Epidemiology of dementia and Alzheimer disease. In: Terry R.D., Katzman R., Bick K.L., and Sisodia S.S. (Eds). Alzheimer Disease. 2nd edition (1999), Lippincott Williams & Wilkins, Philadelphia 95-115
18. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 7 (1984) 939-944
19. Misumi Y., Tanaka Y., and Ikehara Y. Biosynthesis, intracellular processing and secretion of haptoglobin in cultured rat hepatocytes. Biochem. Biophys. Res. Commun. 114 2 (1983) 729-736
20. Monte S.M., Ghanbari K., Frey W.H., Beheshti I., Averback P., Hauser S.L., Ghanbari A., and Wands J.R. Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid. J. Clin. Invest. 100 12 (1997) 3093-3104
21. Morris J.C. The clinical dementia rating (CDR), current version and scoring rules. Neurology 43 11 (1993) 2412-2414
22. Peterson R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., and Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56 (1999) 303-308
23. Pratico D., Clark C.M., Liun F., Rokach J., Lee V.Y., and Trojanowski J.Q. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol. 59 6 (2002) 972-976
24. Ronne H., Ocklind C., Wiman K., Rask L., Oblink B., and Peterson P.A. Ligand dependent regulation of intracellular protein transport: effect of vitamin A on the secretion of retinol-binding protein. J. Cell. Biol. 96 3 (1983) 907-910
25. Shevchenko A., Wilm M., Vorm O., and Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68 5 (1996) 850-858
26. Sjögren M., Davidsson P., Gottfries J., Vanderstichele H., Edman A., Vanmechelen E., Wallin A., and Blenow K. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement. Geriatr. Cogn. Disord. 12 4 (2001) 257-264
27. Sjögren M., Davidsson P., Tullberg M., Minthon L., Wallin A., Wikkelso C., Granerus A.K., Vanderstichele H., Vanmechelen E., and Blenow K. Both total and phosphorylated tau are increased in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 70 5 (2001) 624-630
28. Sjögren M., Minthon L., Davidsson P., Granerus A.K., Clarberg A., Vanderstichele H., Vanmechelen E., Wallin A., and Blenow K. CSF levels of tau, amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J. Neural Transm. 107 5 (2000) 563-579
29. Sousa J.C., Cardoso I., Marques F., Saraiva M.J., and Palha J.A. Transthyretin and Alzheimer's disease: where in the brain?. Neurobiol. Aging 28 5 (2007) 713-718
30. Vanmechelen E., Blennow K., Davidsson P., Cras P., Van de., and Voorde A. Combination of tau/phospho-tau with other biochemical markers for Alzheimer CSF diagnosis and tau in CSF as marker for neurodegeneration. In: Iqbal K., Winblad B., Nishimura T., Takeda M., and Wisniewski H.M. (Eds). Alzheimer's Disease: Biology, Diagnosis and Therapeutics (1997), UK, Wiley Ltd., Chichester 197-203
31. Wassell J. Haptoglobin: function and polymorphism. Clin. Lab. 46 11-12 (2000) 547-552